NASDAQ:SONN Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis $0.86 +0.01 (+1.18%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.82▼$0.8750-Day Range$0.85▼$1.9752-Week Range$0.82▼$10.09Volume37,110 shsAverage Volume72,009 shsMarket Capitalization$2.67 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Sonnet BioTherapeutics alerts: Email Address Sonnet BioTherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3,388.4% Upside$30.00 Price TargetShort InterestHealthy0.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.14) to ($2.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.12 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSonnet BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSonnet BioTherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Sonnet BioTherapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.34% of the float of Sonnet BioTherapeutics has been sold short.Short Interest Ratio / Days to CoverSonnet BioTherapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sonnet BioTherapeutics has recently decreased by 49.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSonnet BioTherapeutics does not currently pay a dividend.Dividend GrowthSonnet BioTherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SONN. Previous Next 2.4 News and Social Media Coverage News SentimentSonnet BioTherapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sonnet BioTherapeutics this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for SONN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Sonnet BioTherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sonnet BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Sonnet BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.45% of the stock of Sonnet BioTherapeutics is held by institutions.Read more about Sonnet BioTherapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sonnet BioTherapeutics are expected to decrease in the coming year, from ($2.14) to ($2.52) per share.Read more about Sonnet BioTherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Sonnet BioTherapeutics Stock (NASDAQ:SONN)Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.Read More SONN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SONN Stock News HeadlinesJuly 25 at 11:07 AM | finanznachrichten.deJTC Team, LLC: Sonnet BioTherapeutics Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamJuly 24 at 8:30 AM | globenewswire.comSonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 StudyJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 28, 2024 | globenewswire.comSonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual MeetingMay 22, 2024 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Review of Strategic AlternativesMay 22, 2024 | finance.yahoo.comSonnet BioTherapeutics Announces Review of Strategic AlternativesMay 15, 2024 | investorplace.comSONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024April 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and HCA Healthcare (HCA)July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.April 17, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)April 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)March 11, 2024 | finance.yahoo.comSonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified ObjectiveMarch 1, 2024 | morningstar.comSonnet BioTherapeutics Holdings Inc Ordinary Shares SONNFebruary 29, 2024 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy VolunteersFebruary 29, 2024 | msn.comSonnet BioTherapeutics Reported SON-1010 Phase I Trial Results: Demonstrates Safety, Efficacy in Melanoma Model, and Potential for Dose EscalationFebruary 17, 2024 | finance.yahoo.comSonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats ExpectationsFebruary 14, 2024 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings UpdateFebruary 7, 2024 | msn.comNasdaq panel expected to decide on Yield10 listing within next monthSee More Headlines Receive SONN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SONN CUSIPN/A CIK1106838 Webwww.chanticleerholdings.com Phone609-375-2227Fax704-366-2463Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$30.00 Low Stock Price Target$30.00 Potential Upside/Downside+3,450.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,830,000.00 Net Margins-11,187.19% Pretax Margin-9,037.59% Return on Equity-382.31% Return on Assets-126.21% Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$150,000.00 Price / Sales17.52 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / Book-6.50Miscellaneous Outstanding Shares3,110,000Free Float3,050,000Market Cap$2.63 million OptionableNot Optionable Beta0.52 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Pankaj Mohan Ph.D. (Age 59)Founder, Chairman, CEO & President Comp: $927kDr. John K. Cini Ph.D. (Age 71)Chief Scientific Officer & Co-Founder Comp: $602.48kMr. Jay Cross (Age 54)Chief Financial Officer Comp: $603.42kMr. Donald J. Griffith CPA (Age 75)CPA, Controller & Director Comp: $134.05kMs. Susan Dexter (Age 69)Chief Technical Officer Dr. Richard T. Kenney FACP (Age 66)M.D., Chief Medical Officer Mr. Manuel DafonsecaHead of Clinical OperationsMore ExecutivesKey CompetitorsPHAXIAM TherapeuticsNASDAQ:PHXMRedHill BiopharmaNASDAQ:RDHLTonix PharmaceuticalsNASDAQ:TNXPKinetaNASDAQ:KAObsEvaNASDAQ:OBSVView All Competitors SONN Stock Analysis - Frequently Asked Questions How have SONN shares performed this year? Sonnet BioTherapeutics' stock was trading at $1.74 on January 1st, 2024. Since then, SONN stock has decreased by 50.6% and is now trading at $0.86. View the best growth stocks for 2024 here. How were Sonnet BioTherapeutics' earnings last quarter? Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) posted its earnings results on Tuesday, May, 14th. The company reported $0.07 earnings per share (EPS) for the quarter. Sonnet BioTherapeutics had a negative net margin of 11,187.19% and a negative trailing twelve-month return on equity of 382.31%. When did Sonnet BioTherapeutics' stock split? Sonnet BioTherapeutics's stock reverse split on the morning of Friday, September 1st 2023. The 1-22 reverse split was announced on Friday, September 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Sonnet BioTherapeutics? Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sonnet BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sonnet BioTherapeutics investors own include Gevo (GEVO), Sorrento Therapeutics (SRNE), Boxlight (BOXL), T2 Biosystems (TTOO), Biocept (BIOC), iBio (IBIO) and Trevena (TRVN). This page (NASDAQ:SONN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
